Displaying drugs 10651 - 10675 of 12610 in total
FP0011
FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Investigational
Matched Description: … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties. ... small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of …
SBT-100
SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Investigational
Matched Description: … SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody ... It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma …
SNS01-T
SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Investigational
Matched Description: … the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine. ... It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets …
BMN-351
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Investigational
Matched Description: … It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD). ... a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of …
Ligelizumab
Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). Similar in mechanism to omalizumab, another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer a greater affinity for free serum IgE and...
Investigational
Matched Description: … Initial trials of ligelizumab suggest a greater efficacy over its predecessor for the treatment of CSU ... anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. ... While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and …
Inactivated SARS-Cov-2 Vaccine
Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone. Double-blind, randomized, placebo-controlled phase 1 (96 participants) and phase 2 (224...
Investigational
Matched Description: … strain of SARS-CoV-2. ... Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 ... [A220158] Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity …
Hypoxanthine
Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Experimental
Matched Description: … of nucleic acids by the salvage pathway. ... Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation …
Glembatumumab vedotin
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Investigational
Matched Description: … for the treatment of melanoma and breast cancer. ... A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E …
Lexaptepid pegol
Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
Investigational
Matched Description: … , End Stage Renal Disease, and Anemia of Chronic Disease. ... Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases …
25-desacetylrifapentine
25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).
Investigational
Matched Description: … Three Doses of Rifapentine and 25-Desacetyl Rifapentine). ... under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of …
Fluorofuranylnorprogesterone F-18
Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Investigational
Matched Description: … Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography). ... Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of …
Ridinilazole
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)). ... Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
Alunacedase alfa
Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Investigational
Matched Description: … Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. ... This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities. …
MGN-4893
MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.
Investigational
Matched Description: … MGN-4893 is an inhibitor of microRNA-451. ... In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera. …
Apelin
Apelin is under investigation in clinical trial NCT03449251 (A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin).
Investigational
Matched Description: … Haemodynamic and Metabolic Effects of Apelin and Relaxin). ... Apelin is under investigation in clinical trial NCT03449251 (A Series of Pilot Studies to Evaluate the …
Ginsenoside Rb1
Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng). Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. Because ginsenosides appear to affect multiple pathways, their effects are complex...
Nutraceutical
Matched Description: … claims of ginseng's efficacy. ... Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant ... Ginsenosides have been the target of research, as they are viewed as the active compounds behind the …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the ... products that have been withdrawn or removed from the market for reasons of safety or effectiveness. …
Trefoil Factor 2
The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most...
Investigational
Matched Description: … in gastric tissues with the source for them being predominantly stromal cells, although expression of ... The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing ... The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected …
XTL-6865
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Investigational
Matched Description: … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis ... It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of …
Dexpramipexole
Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).
Investigational
Matched Description: … the QRS Complex to the End of the T Wave Corrected for Heart Rate)). ... Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of …
Vercirnon
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). ... receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of …
Rexin G
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Investigational
Matched Description: … Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene ... It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of ... It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] …
VTX-801
VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene). It is being investigated in Wilson Disease.
Investigational
Matched Description: … VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an ... AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B …
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
Matched Description: … It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. ... It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection …
Displaying drugs 10651 - 10675 of 12610 in total